Trial reportAlimentary pharmacology & therapeutics2008
Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study.
Trial report in Alimentary pharmacology & therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Association between Helicobacter pylori infection and irritable bowel syndrome: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis.BMC gastroenterology · 2016Pooled it
- Serum correlates of the placebo effect in irritable bowel syndrome.Neurogastroenterology and motility · 2010Trial
- Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome.FASEB bioAdvances · 2022Article
- Aberrant Intraregional Brain Activity and Functional Connectivity in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.Frontiers in neuroscience · 2021Article
- Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea.Frontiers in pharmacology · 2020Review
- Expression and clinical significance of 5-HT and 5-HTExperimental and therapeutic medicine · 2019Article
- Anticipation of thermal pain in diverticular disease.Neurogastroenterology and motility · 2016Article
- Article
- Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.Neurogastroenterology and motility · 2015Article
- Probiotics and irritable bowel syndrome.World journal of gastroenterology · 2013Review
- Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis.The American journal of gastroenterology · 2012Article
- Brain-Gut Interactions in IBS.Frontiers in pharmacology · 2012Article
- The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome.Gastroenterology · 2011Article
- Understanding gastrointestinal distress: a framework for clinical practice.The American journal of gastroenterology · 2011Article
- Serotonin in the gastrointestinal tract.Current opinion in endocrinology, diabetes, and obesity · 2009Review
- Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Gastroenterology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundSymptom improvement in irritable bowel syndrome (IBS) treatment trials varies widely, with only 50-70% of patients qualifying as responders. Factors predicting treatment responsiveness are not known, although we have demonstrated that symptom improvement with the 5-HT3R antagonist alosetron is correlated with reduced amygdala activity.
aimTo determine whether neural activity during rectal discomfort or psychological distress predicts symptom improvement following treatment with alosetron.
methodsBasal psychological distress and neural activity (15O PET) during uncomfortable rectal stimulation were measured in 17 nonconstipated IBS patients who then received 3 weeks of alosetron treatment.
resultsGreater symptom improvement was predicted by less activity in bilateral orbitofrontal cortex (OFC) and medial temporal gyrus during pre-treatment scans. Lower levels of interpersonal sensitivity predicted greater symptom improvement and were positively related to activity in left OFC. Connectivity analysis revealed a positive relationship between activity in the left OFC and right amygdala.
conclusionsIrritable bowel disease symptom improvement with 5-HT3R antagonist alosetron is related to pre-treatment reactivity of the left OFC, which may be partially captured by subjective measures of interpersonal sensitivity. The left OFC may fail to modulate amygdala response to visceral stimulation, thereby diminishing effectiveness of treatment. Psychological factors and their neurobiological correlates are plausible predictors of IBS treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.